Glenmede Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Glenmede Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$221K	Buy	+485	New	+$197K	﹤0.01%	1232

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Glenmede Investment Management's ALNY Position: Q3 2025 in Review

Glenmede Investment Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2025: 485 shares worth $221K. The stake represents ﹤0.01% of the portfolio and ranks #1232 among its holdings.

821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

Glenmede Investment Management held 485 shares of Alnylam Pharmaceuticals worth $221K as of Q3 2025.
Alnylam Pharmaceuticals was a new Glenmede Investment Management position in Q3 2025.
Alnylam Pharmaceuticals made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1232 holding.
821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.